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Abstract  1 
Fibrosis is a common pathological feature of chronic disease. Deletion of the NF-B subunit 2 
c-Rel limits fibrosis in multiple organs, although the mechanistic nature of this protection is 3 
unresolved. Using cell-specific gene-targeting manipulations in mice undergoing liver 4 
damage, we elucidate a critical role for c-Rel in controlling metabolic changes required for 5 
inflammatory and fibrogenic activities of hepatocytes and macrophages, and identify Pfkfb3 6 
as the key downstream metabolic mediator of this response. Independent deletions of Rel 7 
in hepatocytes or macrophages suppressed CCl4-induced liver fibrosis, while combined 8 
deletion had an additive anti-fibrogenic effect. In TGF1-induced hepatocytes, c-Rel 9 
regulates expression of a profibrogenic secretome comprising inflammatory molecules and 10 
CTGF; the latter promoting collagen secretion from hepatic myofibroblasts. Macrophages 11 
lacking c-Rel fail to polarise to M1 or M2 states, explaining reduced fibrosis in RelΔLysM mice. 12 
Pharmacological inhibition of c-Rel attenuated fibrosis in multiple organs in both murine and 13 
human fibrosis. In conclusion, activation of cRel/Pfkfb3 in damaged tissue instigates a 14 
paracrine signalling network between epithelial, myeloid and mesenchymal cells to stimulate 15 
fibrogenesis. Targeting the c-Rel/Pfkfb3 axis has potential for therapeutic applications in 16 










Fibrosis is a pathophysiological response to repeated tissue insults and involves the 3 
progressive accumulation of collagen-rich fibril-forming extracellular matrix (ECM). Fibrosis 4 
can occur in any solid organ and if unchecked will progressively replace and disrupt normal 5 
tissue mass and architecture leading to loss of organ function1–4. A vast range of human 6 
disease states are associated with fibrosis, affecting all vital organs, moreover the 7 
persistence of fibrotic tissue increases the risk of many cancers including breast, lung, liver 8 
and pancreas5–7. Fibrosis is also a feature of tissue ageing and conditions associated with 9 
regenerative failure (e.g. Duchenne Muscular Dystrophy) where the gradual replacement of 10 
functional tissue with fibrotic ECM contributes to frailty, loss of mobility and reduced quality 11 
of life8–10. The huge clinical burden of fibrosis has stimulated intensive research aimed at 12 
the design of anti-fibrotic drugs, this aim has been further stimulated by an increasing body 13 
of evidence that fibrosis is highly dynamic and can be manipulated to slow progression, halt 14 
or even undergo regression1. To unlock effective anti-fibrotics it is imperative we identify the 15 
underlying molecular drivers of fibrosis and identify fibrosis-mediators that can be developed 16 
as pharmacological targets. Of particular interest is the identification of fibrosis-mediators 17 
that have a common (or core) mechanism of action across different organs and types of 18 
injuries, thus enabling the design of generic anti-fibrotic medicines. Common features of 19 
fibrotic tissues are persistent epithelial dysfunction, unresolved inflammation and the 20 
progressive activation and proliferation of ECM-expressing myofibroblasts11–13. These 21 
pathological changes are underpinned by complex multi-directional inflammatory and 22 
fibrogenic crosstalk between these cellular compartments within the fibrogenic niche. 23 
Hence, illuminating factors that drive one or more of these common pathological processes 24 
has the potential to reveal targets for the design of generic anti-fibrotic therapies.  25 
 26 
 6 
The NF-B family of transcription factors (RelA/p65, RelB, c-Rel, p50 and p52) are best 1 
known for their functions in the immune system and as mediators of inflammation14–17. 2 
However, the NF-B proteins participate in broader cellular functions that include the control 3 
of cell proliferation, differentiation, apoptosis, migration, adhesion and senescence, all of 4 
which are implicated in fibrogenesis18–21. Importantly, while each of the NF-B subunits 5 
recognise a common core B DNA binding motif, the transcriptional and physiological 6 
consequences of DNA binding differ between the subunits22. As an example, mice lacking 7 
RelA/p65 die during embryogenesis due to massive hepatocyte apoptosis, by contrast mice 8 
lacking any one of the other four subunits undergo normal embryonic development and are 9 
viable23–25. Although the subunits share common structural features such as the Rel 10 
homology domain and a nuclear localisation sequence, they have quite distinct primary 11 
amino acid sequences and can interact differentially with a range of transcriptional co-factors 12 
to bring about differential gene expression14,18. There is also accumulating evidence for 13 
context and cell-specific functions for the NF-B subunits, some of which are controlled by 14 
specific post-translational modifications, in particular dynamic phosphorylation and 15 
acetylation events18,26.   16 
 17 
c-Rel, which is encoded by the REL gene in humans, is an NF-B activator of gene 18 
transcription. c-Rel can promote a permissive state for transcription not only through its 19 
interaction with B motifs, but also via its regulation of the histone methyltransferase EZH2 20 
27,28, the latter recently identified as a profibrogenic regulator in models of liver disease29. 21 
We previously described that c-Rel is upregulated in chronic disease and functions as a core 22 
pro-fibrogenic factor, based on our observations that c-Rel-deficient (Rel-/-) mice are 23 
protected from fibrosis in liver, heart and skin injury models30–33. However, the cellular 24 
context and the mechanisms by which c-Rel promotes fibrosis are poorly defined and 25 
 7 
evidence is currently lacking that pharmacological targeting of c-Rel can safely and 1 
effectively modulate fibrosis in the context of chronic injury. 2 
 3 
Here we report that c-Rel operates as an essential transcriptional switch for metabolic 4 
reprogramming that is required for energy-dependent phenotypic transitions occurring in 5 
epithelial cells and macrophages in response to tissue injury. These phenotypic transitions 6 
are shown to be important for inflammatory functions and the activation of fibrogenic 7 
signalling networks to promote tissue fibrosis. Hence, c-Rel unexpectedly emerges as a 8 
metabolic regulator of tissue fibrosis and a rationale target for the development of 9 
antifibrotics. We validate this proposal by demonstrating that pharmacological targeting of 10 
c-Rel with a selective small molecule inhibitor prevents fibrosis and promotes normal tissue 11 
regeneration. Our data therefore set the scene for the design of targeted c-Rel inhibitors as 12 
anti-fibrotic agents for use across multiple organs and disease processes. 13 
 14 
Results  15 
c-Rel regulates the epithelial response to damage  16 
Examination of the expression of c-Rel in fibrotic human liver, kidney and lung revealed a 17 
previously unreported upregulation of the NF-B transcription factor in epithelial cells of all 18 
three tissues (Figure 1a and Supplementary Figure 1). Enhanced c-Rel expression was 19 
common in chronic liver, lung and kidney diseases and in the latter positively correlated with 20 
disease progression (Figure 1b, Extended data Figure 1a and 1b). Epithelial damage is 21 
often an initiating event for triggering wound repair and in the context of an acute injury is 22 
resolved by epithelial regeneration1,34. To determine the role of epithelial c-Rel in acute 23 
wound healing in the liver, we generated RelΔAlb mice in which the transcription factor is 24 
selectively deleted in hepatocytes and cholangiocytes (Extended data Figure 1c). As the 25 
founder Relfl/fl line was genetically engineered to express GFP upon Cre-mediated 26 
 8 
recombination we were able to use flow cytometry of isolated cells to confirm epithelial-1 
targeted recombination (Figure 1c). Relfl/fl and RelΔAlb mice were subjected to acute liver 2 
injury with the hepatotoxin carbon tetrachloride (CCl4). Immunohistochemical staining for c-3 
Rel confirmed increased expression and nuclear localisation in hepatocytes of CCl4 injured 4 
Relfl/fl mice compared to controls. As anticipated, c-Rel was absent in hepatocytes of CCl4 5 
injured RelΔAlb mice, whereas strong immunoreactivity was detected in infiltrating immune 6 
cells (Figure 1d). Histology of damaged Relfl/fl (wild type) liver revealed increased numbers 7 
of -SMA+ myofibroblasts (Figure 1e) which correlated with inflammatory gene expression 8 
(Extended data Figure 1d). These responses were blunted in CCl4-injured RelΔAlb mice 9 
despite the liver damage markers ALT and AST being at similar levels to Relfl/fl controls 10 
(Supplementary Table 1). We next asked if deletion of c-Rel impacts on hepatocellular 11 
regeneration following CCl4-injury and found enhanced numbers of proliferative hepatocytes 12 
in damaged RelΔAlb liver relative to Relfl/fl control (Figure 1f). Of note, cell-specific deletion 13 
of c-Rel in hepatic myofibroblast (HM, RelΔLrat mice) did not affect the extent of liver injury or 14 
the acute wound healing response (Extended data Figure 1e, Supplementary Table 1). 15 
We conclude that injury-induced activation of c-Rel in the hepatic epithelium promotes a 16 
profibrogenic phenotype. Liver damage impacts on hepatocytes in multiple ways incuding 17 
triggering cellular stress responses, stimulation of apoptosis or senescence and secretion 18 
of pro-inflammatory and pro-fibrogenic mediators to mount an effective wound healing 19 
response12,35. Indeed, epithelial cells have been proposed as critical orchestrators of 20 
immune and inflammatory events following tissue stress and damage36. We therefore 21 
hypothesised that the upregulation of c-Rel we observed in the hepatic epithelium of 22 
damaged human liver (Figure 1a and b) may control hepatocyte plasticity to promote 23 
proinflammatory and profibrogenic phenotypes under disease conditions.  24 
 25 
 9 
To test this hypothesis we first measured the secretion of several pro-inflammatory cytokines 1 
and chemokines in primary cultures of WT and Rel-/- hepatocytes exposed to the classic 2 
inflammatory trigger IL-1 (Figure 2a). As expected, WT Hepatocytes mounted a robust 3 
inflammatory response to IL-1 challenge, but by contrast Rel-/- hepatocytes were defective 4 
for induction of Il-6, Cxcl1, Cxcl2, Ccl3 and Ccl5. These data suggest that activation of c-Rel 5 
facilitates the aquisition of an inflammatory hepatocellular phenotype.To confirm a pivotal 6 
role for hepatocellular c-Rel in vivo we determined the effects of hepatocyte-specific deletion 7 
of the Rel gene on the inflammatory response to acute toxic damage by CCl4. Hepatocyte-8 
targeted deletion of Rel (RelΔhep) was achieved by delivery of AAV8-TBG-Cre to the livers of 9 
Relfl/fl mice and confirmed by c-Rel immunohistochemical staining of the acute CCl4 injured 10 
livers (Extended data Figure 2a). Neutrophil and macrophage recruitment in response to 11 
CCl4 damage was blunted in RelΔhep livers as was the induction of proinflammatory cytokines 12 
and chemokines (Figure 2b and Extended data Figure 2b). Induction of a robust 13 
inflammatory response and immune cell recruitment following injury is critical to drive 14 
fibrogenesis37,38.  These data indicate c-Rel is a regulator of the hepatocyte phenotype and 15 
contributes to fibrogenesis via regulation of damage-induced reprogramming to a pro-16 
inflammatory state.  17 
 18 
TGF1 is expressed by macrophages and activated myofibroblasts in response to tissue 19 
injury and is a key mediator of wound healing and fibrogenesis39. In addition, TGF1 20 
modulates epithelial homeostasis and in the liver can influence hepatocyte apoptosis, 21 
senescence, regeneration and inflammation. As these processes are also under the control 22 
of NF-B, it was of interest to determine the extent to which c-Rel regulates the response of 23 
hepatocytes to TGF1 stimulation. To this end we determined the secretome of TGF1-24 
stimulated cultured hepatocytes, using a targeted Meso Scale Discovery (MSD) screen for 25 
the detection of inflammatory molecules and an unbiased proteomics analysis for detection 26 
 10 
of epithelial and fibrogenic proteins. MSD analysis revealed that similar to IL-1 challenge, 1 
exposure of WT hepatocytes to TGF1 stimulates the secretion of several classic 2 
inflammatory cytokines, of which Il-6, Cxcl1, Cxcl2, Ccl3, Ccl4 and Ccl5 responses were 3 
significantly supressed in Rel deleted hepatocytes (Figure 2c). While TGF is best known 4 
for its strong anti-inflammatory effects, these data, in conjuction with previous reports reveal 5 
TGF1-dependent inflammatory phenotypes in hepatocytes40–44. This suggests a 6 
dichotomous role for TGF in hepatocytes, which is in line with its context-dependent 7 
dampening or promotion of immune responses45. To corroborate the role of c-Rel in TGF1-8 
induced epithelial inflammation we examined responses in primary renal proximal tubular 9 
cells (PTEC). TGF1 stimulation induced enhanced gene expression of Il-6, Cxcl1, Cxcl2, 10 
Ccl2, Ccl4 and Ccl5, all of which were attenuated in c-Rel-deficient PTECs (Extended data 11 
Figure 2c).  12 
 13 
Proteomic analysis of WT hepatocyte media revealed that TGF1 challenge altered the 14 
secretion of 321 different proteins, confirming a phenotypic reprogramming of these cells in 15 
reponse to fibrogenic stimuli (Figure 2d). To determine whether c-Rel signalling was 16 
important in modulating the sectrome of TGF1 stressed hepatocytes, we directly compared 17 
differentially regulated proteins detected in the sectrome of WT hepatocytes after TGF1 18 
stimulation with the secretome of Rel-/- hepatocytes after TGF1 challenge. Comparison of 19 
these two datasets revealed 125 differentially secreted proteins regulated by TGF1 20 
challenge, of which 55 were dependent on c-Rel for their response to TGF1 (Figure 2d 21 
and e). Proteins secreted at enhanced levels in a c-Rel-dependent manner included the 22 
fibrogenic factors bone morphometric protein 1 (BMP1), connective tissue growth factor 23 
(CTGF), cathepsin D (CTSD) and serpine 1 (Extended data Figure 2d) 46–50, these 24 
observations leading us to hypothesise that c-Rel signalling in hepatocytes promotes the 25 
secretion of profibrogenic factors. Hepatocytes have been described as a source of CTGF 26 
 11 
in the fibrotic niche and this growth factor has a plethora of fibrogenic actions including 1 
myofibroblast activation, extracellular matrix sectretion, tissue remodelling and 2 
angiogenesis51,52. Immunohistochemical staining confirmed that CTGF was highly 3 
expressed in hepatocytes and HM of acute CCl4 injured Relfl/fl mice and this induction was 4 
suppressed specifically in RelΔhep hepatocytes, this confirming regulation of epithelial-5 
derived CTGF expression by c-Rel  (Figure 2f). To investigate the role of CTGF downstream 6 
of c-Rel, we performed a rescue experiment by supplementing the media of TGF1-7 
stimulated Rel-/- precision cut liver slices (PCLS) with recombinant CTGF. Soluble collagen 8 
release was blunted in TGF1 stimulated Rel-/- PCLS, but consistent with our hypothesis, 9 
Rel-/- PCLS exposed to exogenous CTGF restored their soluble collagen production to levels 10 
comparable with TGF1 stimulated WT PCLS (Extended data Figure 2e). On the basis of 11 
these data we  propose that paracrine activation of epithelial c-Rel stimulates expression of 12 
a pro-inflammatory and pro-fibrogenic secretome, important for the initiation of hepatic 13 
inflammation and wound repair. 14 
 15 
 16 
c-Rel controls a glycolytic switch required for epithelial reprogramming and fibrosis  17 
Phenotype reprogramming, inflammation and fibrogenesis are energy dependent 18 
processes, requiring underlying metabolic changes to support transcriptional and post-19 
transcriptional alterations in gene expression53–55. Seahorse analysis revealed that both 20 
glycolytic rate and mitochondrial respiration were supressed in TGF1 stimulated Rel-/- 21 
hepatocytes relative to controls (Figure 2g and Extended data Figure 3a). To determine 22 
the mechanistic basis for this observation we examined expression of the glycolytic enzymes 23 
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-1 and -3 (Pfkfb1 and Pfkfb3), the 24 
former acting to reduce glycolytic rate while the latter promotes glycolytic flux56. Pfkfb3 25 
expression was elevated in response to chronic CCl4 liver injury and was most noteably 26 
 12 
present within hepatocytes (Figure 2h). TGF1 increased Pfkfb3 transcript levels in WT 1 
hepatocytes, by contrast this response was impaired in Rel-/- hepatocytes (Figure 2i). Pfkfb1 2 
expression in WT hepatocytes was unaffected by TGF1 stimulation, however Pfkfb1 mRNA 3 
levels were lower in Rel-/- hepatocytes relative to WT hepatocytes (Extended data Figure 4 
3b). Pfkfb3 transcription was also induced in response to classical inflammatory signals in 5 
WT hepatocytes, however this response was impaired in Rel-/- hepatocytes (Extended data 6 
Figure 3c). In silico analysis of the Pfkfb1 and Pfkfb3 promoters predicted potential for 7 
recruitment of c-Rel based on the presence of multiple putative B binding sites in proximal 8 
and distal promoter regions of both genes (Extended data Figure 3d). ChIP assays 9 
confirmed the recruitment of c-Rel to the distal and proximal sites of the Pfkfb3 promoter 10 
upon stimulation with TGF1 (Extended data Figure 3e). Consistent with gene expression 11 
data, c-Rel binding at the Pfkfb1 promoter was independent of TGF1 (Extended data 12 
Figure 3e).  13 
 14 
From these data we hypothesised that the proinflammatory and profibrogenic effects of c-15 
Rel activation in hepatocytes is dependent upon induction of Pfkfb3 expression and an 16 
increased glycolytic flux. To test this idea we generated hepatocyte-targeted knockouts of 17 
Pfkfb3 (Pfkfb3Δhep) by administration of AAV8-TBG-Cre in Pfkfb3fl/fl mice (Extended data 18 
Figure 3f). Hepatocytes isolated from Pfkfb3Δhep livers failed to undergo TGF1-induced 19 
enhanced lactate production and a concomitant reduction in media glucose that was 20 
observed in control Pfkfb3fl/fl hepatocytes (Extended data Figure 3g). To determine the 21 
consequences of this metabolic defect in vivo, Pfkfb3Δhep and control Pfkfb3fl/fl mice were 22 
subject to acute injury with CCl4. Despite comparable levels of damage, Pfkfb3Δhep livers 23 
were impaired for recruitment of neutrophils and macrophages, and in addition displayed 24 
reduced numbers of SMA+ myofibroblasts (Supplementary Table 1 and Figure 2j). 25 
Consistent with these histological observations, hepatic inflammatory and fibrogenic gene 26 
 13 
expression was suppressed in CCl4-injured Pfkfb3Δhep mice relative to Pfkfb3fl/fl controls 1 
(Figure 2k). A role for Pfkfb3 in fueling the energetic requirements for an hepatocellular 2 
phenotypic switch was further consolidated by in vitro experiments in which TGF1 treated 3 
hepatocytes isolated from Pfkfb3Δhep mice failed to induce the robust inflammatory response 4 
observed in relative Pfkfb3fl/fl controls (Extended data Figure 3h). In addition, hepatocyte 5 
deletion of Pfkfb3 suppressed induction of CTGF (Extended data Figure 3i). These results 6 
were further validated by treatment of WT hepatocytes with a small molecule Pfkfb3 inhibitor 7 
which blocked TGF1-induced secretion of inflammatory cytokines, chemokines (Extended 8 
data Figure 3j) and CTGF (Extended data Figure 3k). 9 
 10 
Of note, we additionally observed c-Rel-dependent upregulation of the transcription factor 11 
Snail in the nucleus of hepatocytes of CCl4 damaged livers and tubular cells of UUO injured 12 
kidneys as well as TGF1-stimulated hepatocyte and proximal tubule cell cultures 13 
(Extended data Figure 4a-e). ChIP assays confirmed c-Rel is recruited to proximal and 14 
distal regions of the Snail promoter which contains multiple NF-B binding sites (Extended 15 
data Figure 4f). Snail is known for its role in epitheial mesenchymal transition (EMT), a 16 
developmental process that promotes progression of cancers. While EMT clearly does not 17 
directly contribute to the generation of fibroblasts in the liver or kidney as show by elegant 18 
lineage tracing studies57,58, it has been suggested that reprogramming of hepatocytes or 19 
renal epithelial cells, also described as “partial EMT”, without directly contributing to the 20 
myfibroblast population can modulate fibrosis as shown by epithelial Snail1 deletion in renal 21 
and liver fibrosis59,60. Interestingly, Snail suppresses the expression of fructose-1,6-22 
bisphosphatase (FBP1), a key enzyme gluconeogenesis61. Hence, c-Rel may promote 23 
glycolysis and epithelial reprogramming through combined direct regulation of Pfkfb3 and 24 
indirect Snail-mediated repression of FBP1. 25 
  26 
 14 
To determine if metabolic control of epithelial reprogramming by c-Rel is relevant in the 1 
context of a chronic tissue injury we determined the effects of selective hepatocellular 2 
deletion of c-Rel in the chronic CCl4 injury model. Using this model, liver fibrosis was 3 
compared between Relfl/fl and RelΔAlb genotypes and we also included a myeloid-specific 4 
deletion of Rel (RelΔLysM) for further comparison. Morphometric analysis (Figure 3a) of 5 
Picrosirius red (collagen) and SMA stained liver sections (Extended data Figure 5a) 6 
evidenced a suppression of fibrosis in RelΔAlb compared to Relfl/fl mice, this confirming a 7 
requirement of epithelial c-Rel for optimal fibrogenesis. However, as also shown in Figure 8 
3a, a similar protective response was also seen in RelΔLysM mice, this raising the potential 9 
for an unexpected profibrogenic role of c-Rel in macrophages. Of note, liver damage, as 10 
assessed by elevated serum ALT and AST, was comparable in all three genotypes 11 
(Supplementary Table 1). 12 
 13 
c-Rel is required for macrophage polarisation 14 
High power images revealed nuclear expression of c-Rel in macrophages of fibrotic human 15 
liver, kidney and lung (Figure 3b and Extended data Figure 5b). As functions for c-Rel in 16 
macrophages are poorly defined, we asked if a deficiency of c-Rel impacts on macrophage 17 
differentiation. Remarkably, both M1 and M2 differentiation were defective in c-Rel-deficient 18 
bone marrow-derived macrophages (Figure 3c-d and Extended data Figure 5c). We next 19 
investigated if the impaired polarisation of c-Rel-deficient bone marrow-derived 20 
macrophages was associated with a failure of metabolic switches required for these 21 
macrophage polarisation processes. Assays for glycolytic rate and mitochondrial respiration 22 
revealed that Rel-/- macrophages are defective for increased respiration associated with M2 23 
differentiation and for enhanced glycolysis associated with M1 differentiation (Figure 3e and 24 
Extended data Figure 5d). Pfkfb1 and Pfkfb3 are required for M2 and M1 states 25 
respectively56,62 and were expressed at diminished levels in Rel-/- macrophages 26 
 15 
differentiated to these functional states (Figure 3f). ChIP assays indicated the enrichment 1 
of c-Rel at the proximal promoter of Pfkfb1 in M2 macrophages (with no c-Rel binding in M0 2 
or M1), while conversely c-Rel recruitment to the Pfkfb3 proximal promoter was only 3 
detected in M1 macrophages (Extended data Figure 5e). We conclude that c-Rel 4 
orchestrates metabolic reprogramming required for macrophage polarisation, this explaining 5 
the protection of RelΔLysM mice from fibrosis. 6 
 7 
 c-Rel combines in epithelial and macrophage compartments to promote fibrosis 8 
Epithelial cells and macrophages extensively crosstalk during wound healing to bring about 9 
effective inflammatory and regenerative responses39. We therefore asked the degree to 10 
which c-Rel is required for epithelial-macrophage signalling crosstalk. To address this, 11 
Relfl/fl, RelΔAlb and RelΔLysM mice were acutely injured with CCl4 prior to isolation of 12 
macrophages and hepatocytes during the inflammatory or resolution phases of wound 13 
healing (Figure 4a). Hepatic recruitment and polarisation of macrophages was as expected 14 
in acute CCl4 injured Relflfl mice but significantly impaired in RelΔLysM mice (Figure 4b-c). 15 
Less expected was that recruitment and polarisation of inflammatory macrophages isolated 16 
from CCl4 injured RelΔAlb mice was also diminished (Figure 4b-c). We next asked if c-Rel 17 
signalling in macrophages is required for hepatocyte inflammatory reprograming. 18 
Hepatocytes isolated from CCl4 injured Relflfl mice confirmed the anticipated expression of 19 
inflammatory genes which was suppressed in CCl4 injured RelΔAlb mice (Figure 4d). 20 
Similarly, expression of inflammatory markers was reduced in hepatocytes from RelΔLysM 21 
mice, indicating that monocyte/macrophage c-Rel is critical for hepatocytes to adopt a 22 
proinflammatory phenotype (Figure 4d). Normal wound healing and aberrant tissue fibrosis 23 
are governed by multi-directional cellular communication between epithelial cells, 24 
macrophages and fibroblasts/myofibroblasts within the wound healing niche. To evaluate 25 
the role of c-Rel signalling in hepatocytes and/or macrophages on hepatic stellate cell (HSC) 26 
 16 
activation, we cultured freshly isolated HSC with conditioned media (CM) collected from 1 
either WT or Rel-/-  hepatocytes or M1 or M2 polarised macrophages. HSC activation, as 2 
measured by SMA expression and cellular morphology, was accelerated for HSC exposed 3 
to CM from TGF1-stimulated WT hepatocytes or WT M2 macrophages but not WT M1 4 
macrophages. Consistent with an attenuation of fibrogenic responses in vivo, CM from Rel-5 
/- hepatocytes or M2 polarised macrophages failed to stimulate HSC activation (Figure 4e-6 
f). 7 
The fibrogenic properties of TGF1-stimulated hepatocytes can be at least in-part explained 8 
by their secretion of factors such as BMP1, CTGF, CTSD and Serpin 1 (Figure 2c and 9 
Extended data Figure 2d). A similar proteomic analysis was performed on the secretome 10 
of cultured WT and Rel-/- M0, M1 and M2 polarised macrophages which identified Galectin 11 
1, Galectin 3, vimentin and MMP12 as profibrogenic factors that are expressed at 12 
significantly lower levels in the media of Rel-/- M2 polarised macrophages compared with 13 
WT (Extended data Figure 5f-g). Collectively, these data reveal a complex signalling 14 
network between hepatocytes, macrophages and HM, of which c-Rel signalling in both 15 
hepatocytes and macrophages is critical for the robust activation of HM and to evoke a 16 
fibrogenic response (Figure 4g). 17 
 18 
To determine the generality of requirement of epithelial and myeloid c-Rel for fibrogenesis 19 
we generated mice in which c-Rel was selectively deleted in kidney (RelΔTEC) or lung 20 
epithelium (RelΔAEC) by retrograde ureteric injection or intratracheal administration 21 
respectively, of an AAV9-CMV-Cre. Flow cytometry of isolated cells as well as ex vivo 22 
fluorescence imaging of whole organs confirmed epithelial-targeted recombination and 23 
expression of GFP (Extended data Figure 6a-c). We then employed the unilateral ureteric 24 
obstruction (UUO) and bleomycin models of chronic kidney and lung damage to compare 25 
response in epithelial, myeloid (RelΔLysM) and control backgrounds. Picrosirius red, SMA 26 
 17 
staining and fibrogenic gene expression revealed similar protective effects of epithelial- or 1 
myeloid-targeted knockout of Rel in both the kidney and lung (Figure 5a-b and Extended 2 
data Figure 6d). In the lung we also observed a significant decrease in hydroxyproline levels 3 
in RelΔAEC and RelΔLysM mice despite comparable levels of tissue injury and cell death 4 
(Extended data Figure 6e-f). Noteworthy was that inflammatory infiltrates and markers 5 
were also reduced in the damaged RelΔTEC kidney and RelΔAEC lungs compared with 6 
controls, this supporting our proposal that c-Rel regulates inflammatory programming of the 7 
damaged epithelium (Extended data Figure 6g-h). 8 
 9 
Dual hepatocyte and macrophage Rel deletion enhances suppression of fibrosis  10 
To determine the physiological impact of perturbation of combined c-Rel signalling in 11 
hepatocytes and macrophages we established an experimental protocol for dual in vivo 12 
knockout of c-Rel (Figure 6a). In this experiment, Relfl/fl and RelΔLysM mice were transduced 13 
with an AAV8-TBG-Cre virus to generate hepatocyte knockout either alone (RelΔHep) or in 14 
combination with macrophage specific deletion of c-Rel (RelΔHep/ΔLysM). GFP expression in 15 
hepatocytes and macrophages from these lines confirmed the anticipated genotypes 16 
(Extended data Figure 7a-b). We then subjected Relfl/fl, RelΔHep, RelΔLysM and RelΔHep/ΔLysM 17 
to chronic CCl4 liver damage for 8 weeks to induce fibrosis. Liver injury (elevated serum 18 
transaminases) was comparable in all four genotypes (Supplementary Table 1). As 19 
previously shown in Figure 3a, deletion of c-Rel in either hepatocytes or macrophages 20 
suppressed fibrosis as determined by quantification of Picrosirius red and SMA stained 21 
liver sections as well as fibrogenic gene expression (Figure 6b-c and Extended data 22 
Figure 7c). Fibrosis and myofibroblast accumulation were further reduced in RelΔHep/ΔLysM 23 
mice indicative of an additive protective effect, consolidating our hypothesis that c-Rel 24 
signalling is required in both cellular compartments for induction of a robust fibrogenic 25 
response. By also quantifying CD68+ monocyte/macrophages we were able to show that 26 
 18 
underlying the dual protective effect of RelΔHep/ΔLysM knockout on fibrosis was an enhanced 1 
suppression of inflammation compared with RelΔHep and RelΔLysM livers (Figure 6d).  2 
 3 
Hepatocyte regeneration is subject to cell-specific regulation by c-Rel 4 
Quantification of numbers of PCNA positive hepatocytes in chronic CCl4 injured livers again 5 
confirmed the stimulatory effects of hepatocyte-targeted deletion of c-Rel (Figure 6e). But 6 
noteworthy was a suppression of hepatocyte proliferation in RelΔLysM mice relative to Relfl/fl 7 
controls. Moreover, in combined RelΔHep/ΔLysM knockouts numbers of proliferative 8 
hepatocytes were similar to those in Relfl/fl mice but intermediate between the 9 
measurements for  RelΔHep and RelΔLysM livers (Figure 6e). To investigate these apparently 10 
contradictory observations, we performed a 70% partial hepatectomy in RelΔAlb and RelΔLysM 11 
mice. Consistent with data from acute toxic liver injury (Figure 1f), hepatocyte proliferation 12 
was significantly increased in regenerating RelΔAlb livers, however by contrast we observed 13 
suppressed hepatocyte proliferation in regenerating RelΔLysM livers (Extended data Figure 14 
8a-b). Expression of cell cycle genes and the mitogenic factors HGF and EGF were elevated 15 
in the regenerating livers of RelΔAlb mice, however these mitogenic responses were 16 
suppressed in RelΔLysM mice (Extended data Figure 8c), these data being consistent with 17 
the regenerative phenotypes observed. These data support previous observations that 18 
hepatocyte regeneration is determined by signalling crosstalk from parenchymal and non-19 
parenchymal cells and indicate cell-specific influences for c-Rel, with suppressive effects in 20 
hepatocytes and stimulatory properties in macrophages. Of note, we have previously 21 
reported that global deletion of c-Rel causes defective hepatocyte proliferation, this likely to 22 
reflect pro-regenerative functions for the NF-B subunit in other resident non-parenchymal 23 
liver cells and infiltrating immune cells 63.  24 
 25 
Pharmacological inhibition of c-Rel suppresses fibrosis 26 
 19 
The data described above led us to investigate the therapeutic potential of targeting of c-1 
Rel using the small molecule inhibitor IT-603 64. We began by showing that IT-603 selectively 2 
inhibits transcription from an NF-B reporter construct co-expressed with a c-Rel expression 3 
vector, but of note the inhibitor had no effect on RelA-stimulated NF-B activity  (Extended 4 
data Figure 9a). We next determined the effects of intraperitoneal administration of IT-603 5 
in models of acute liver (CCl4), chronic kidney (UUO) and chronic lung (bleomycin) damage. 6 
In all three models, IT-603 suppressed fibrogenesis characterised either by Picrosirius red 7 
stained collagen or histological examination of SMA stained tissues (Figure 7a-c and 8 
Extended data Figure 9b-c). To evaluate the anti-fibrotic potential for c-Rel inhibition in 9 
established disease, IT-603 was administered therapeutically in the methionine choline 10 
deficient diet (MCD) model of steatosis-induced liver fibrosis. In addition, effects of IT-603 11 
were determined in pre-established and progressive chronic CCl4-induced liver injury. In 12 
both models, ongoing hepatic fibrogenesis was significantly reduced by therapeutic 13 
intervention with IT-603 (Figure 7d-e, Extended data Figure 9d-g), this despite 14 
comparable levels of liver injury (Supplementary Table 1).  15 
 16 
To translate these findings to humans we assessed the therapeutic effects of IT-603 in 17 
precision cut tissue slices (PCS). PCS cultures were established from the undamaged liver 18 
and kidney which were stimulated with TGF1 to induce fibrosis (Extended data Figure 19 
10a)65. Of note, resident macrophages were present in the appropriate anatomical location 20 
in cultured PCS from both organs (Extended data Figure 10b). Remarkably, IT-603 21 
ameliorated TGF1-induced fibrosis (Picrosirius red) and myofibroblast activation (SMA 22 
positivity) in liver and kidney PCS (Figure 8a-b and Extended data Figure 10c-d). 23 
Quantification of soluble collagen 1a1 protein and the pro-fibrotic neo-epitope pro-C366, in 24 
the PCS media confirmed the potent anti-fibrotic properties of IT-603 in both human tissues 25 
(Figure 8c-d and Extended data Figure 10e-f). Moreover, these dramatic anti-fibrotic 26 
 20 
actions occurred in the absence of any obvious cytotoxicity (Figure 8e and Extended data 1 
Figure 10g). We conclude that pharmacological targeting of c-Rel with IT-603 is potently 2 
anti-fibrotic both in animal and human models of chronic tissue damage. 3 
 4 
Discussion 5 
Fibrogenesis is an active and energy dependent process characterised by dynamic 6 
reprogramming of the phenotype and functions of multiple cell types. The concept of a 7 
“glycolytic switch” being required for cells to achieve a phenotypic change has emerged from 8 
a growing body of literature from investigators studying cell differentiation in a variety of cell 9 
lineages including T cells, dendritic cells and neurons67–70. In the context of fibrosis a role 10 
for metabolic reprogramming is also beginning to emerge, with recent reports that glycolysis 11 
inhibitors can suppress fibrosis in models of lung and renal damage71–73. However, the 12 
mechanisms for control of the glycolytic switch in wound healing and fibrosis are not well 13 
defined. Here we reveal that damage-induced activation of c-Rel in the liver stimulates 14 
expression of the glycolytic regulator Pfkfb3 in both hepatocytes and macrophages. In the 15 
absence of c-Rel/Pfkfb3 neither hepatocytes or macrophages are able to adopt a 16 
profibrogenic phenotypic state. Hence, the simultaneous targeted deletion of c-Rel in both 17 
of these cellular compartments was found to result in profound suppression of liver fibrosis. 18 
By genetically perturbing c-Rel/Pfkfb3 signalling in epitheial and macrophages we have 19 
illuminated a complex multicellular and multidirectional paracrine signalling network that 20 
drives progression of fibrosis in both the liver and kidney. 21 
 22 
Our model for c-Rel/Pfkfb3 control of fibrosis proposes that it is required for hepatocytes to 23 
adopt an activated phenotype whereby they express a cytokine-rich secretome that 24 
promotes the fibrogenic activities of macrophages and activated HSC (Figure 4g). Recently, 25 
single cell RNAseq anlaysis of human liver identified six transcriptionally distinct hepatocyte 26 
 21 
populations, of which one cluster displayed a distinct inflammatory and fibrogenic state74. 1 
Similarly in a mouse model of cholestatic liver injury, scRNA-seq analysis identified four 2 
hepatocyte clusters directly linked to inflammatory processes75. We have demonstrated that 3 
TGF1 is likely to be pivotal for amplification of these hepatocyte phenotypes in the 4 
fibrogenic milieu. TGF1 is produced by activated macrophages and HSC and we have 5 
confirmed that it stimulates hepatocytes to secrete a variety of cytokines with the ability to 6 
promote paracrine positive feedback stimulation to both macrophages and HSC. We have 7 
shown how c-Rel is required for these TGF1-induced responses including hepatocyte 8 
secretion of CTGF, which is well known for its ability to enhance collagen production by 9 
activated HSC76–78. To note, CTGF has previously been described to be produced by 10 
hepatocytes by an incompletely defined TGF1-dependent mechanism79–81. Our work now 11 
highlights a critical role for c-Rel for TGF1 stimulation of hepatocytes. We propose that the 12 
combined activation of the c-Rel/Pfkfb3 metabolic axis in macrophages and hepatocytes 13 
maintains a network of paracrine signals that perpetuate inflammation and myofibroblast 14 
collagen production in the non-healing tissue microenvironment.  15 
 16 
An extensive literature describes the role of classical canonical NF-B (RelA/p50) signalling 17 
in tissue fibrosis14. Several independent research groups, including our own, have reported 18 
that global inhibition of canonical NF-B inhibits fibrosis across multiple organs and disease 19 
models30,31,82–84. Canonical NF-B is critically dependent on its upstream kinase IKK, the 20 
latter once being a major focus for drug development85,86. We have previously described 21 
how IKK inhibitors inhibit liver fibrosis and promote its regression by stimulating apoptosis 22 
of myofibroblasts87,88. However, IKK inhibition is associated with significant toxicities, these 23 
in-part reflecting the essential role of canonical NF-B signalling in immunity and epithelial 24 
cell survival89–92. There is also concern over the non-NF-B targets of IKK inhibitors which 25 
makes this approach less specific than originally anticipated93. In contrast to the extensive 26 
 22 
pharmacological investigation of IKK, drug targeting of the non-classical NF-B 1 
transcription factors (c-Rel and RelB) has received surprisingly little attention85. Mice lacking 2 
c-Rel are viable and despite reports of functions for c-Rel in T cell development have a 3 
functional and healthy immune system without signs of autoimmune disease27. Hence, c-4 
Rel emerges from our work as a promising new pharmacological target for the design of 5 
anti-fibrotic strategies. That rationale is strengthened by the recent discovery of molecules 6 
with specificity for inhibition of c-Rel DNA binding and transcriptional activity including the 7 
thiohydantoin IT-603 used in our studies and the napthalenethiobarbituate IT-90164,94. Our 8 
finding that IT-603 is a potent anti-fibrotic in human as well as murine pre-clinical models of 9 
liver and kidney fibrosis adds to the therapeutic opportunities for these molecules, which 10 
also includes cancer and transplantation94–96. Moreover, by defining the molecular 11 
mechanisms by which c-Rel stimulates fibrosis we provide a strong justification for further 12 
pre-clinical development of small molecule inhibitors of c-Rel and its downstream metabolic 13 





 Human Biopsies 19 
Collection and use of human tissue was ethically approved The North East - Newcastle and 20 
North Tyneside 1 research committee. Human kidney tissue from surgical resections was 21 
obtained under full ethical approval (REC 13/EM/0311) and patient consent. Normal human 22 
kidney tissue was obtained from patients undergoing surgical resection. Renal biopsies 23 
were obtained from patients diagnosed with either focal segmented glomerulosclerosis 24 
(FSGS) or diabetic nephropathy.  25 
 23 
Human liver tissue from surgical resections were obtained under full ethical approval 1 
(H10/H0906/41) and through the CEPA biobank (17/NE/0070) and used subject to patients 2 
written consent. Liver disease cohort consisted of patients diagnosed with alcoholic liver 3 
disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and primary biliary 4 
cirrhosis. Control human liver tissue was collected from patients undergoing cancer surgical 5 
resections.  6 
Diseased human lung tissue was collected from patients undergoing either double or single 7 
lung transplants under full ethical approval (REC 11/NE/0291) and informed written consent 8 
from all study patients. Control human lung tissue was obtained from unused transplant 9 
lungs under full ethical approvals and informed consent from both donor families and lung 10 




All animal experiments were approved by the Newcastle Ethical Review Committee and 15 
performed under a UK Home Office licence in accordance with the ARRIVE guidelines. 16 
Experiments using Pfkfb3fl/fl mice97 were performed collaboratively in the laboratory of Peter 17 
Carmeliet (Leuven) and approved by the Newcastle Ethical Review Committee and the  18 
Animal Ethics Committee of KULeuven. Mice were housed in pathogen-free conditions and 19 
kept under standard conditions with a 12-hour day/night cycle and access to food and water 20 
ad libitum, at a temperature between 20-24C (average 21C) and a humidity of 55%. Power 21 
calculations were not routinely performed; however, animal numbers were chosen to reflect 22 
the expected magnitude of response taking into account the variability observed in previous 23 
experiments. In vivo and in vitro experiments were performed on either C57BL/6 J Wild-24 
Type (WT) control mice or c-Rel knockout mice (Rel-/-) on a C57BL/6 J background. Relfl/fl 25 
were crossed with Alb-cre+/- or LysM-cre+/- or Lrat-cre+/- mice to generate Alb-cre+/- Relfl/fl 26 
 24 
(RelΔAlb), LysM-cre+/- Relfl/fl (RelΔLysM) or Lrat-cre+/- Relfl/fl (RelΔLrat) mice (Jax labs stock No: 1 
02434198, stock No: 004781 and stock No: 00357499. Relfl/fl mice are genetically engineered 2 
to express GFP upon Cre-mediated recombination. Adeno-associated virus mediated Cre 3 
recombinase delivery was used to target the epithelial cells of the liver, kidney and lung. 4 
Briefly, to deplete c-Rel or Pfkfb3 in hepatocytes, Relfl/fl or RelΔLysM or Pfkfb3fl/fl mice received 5 
a single intravenous tail vein injection of 1x1011 p.f.u. of AAV8-TBG-Cre to generate RelΔHep, 6 
RelΔHep/ΔLysM and Pfkfb3Δhep mice respectively. To deplete c-Rel in epithelial cells in the 7 
kidney Relfl/fl mice received a retrograde ureteric injection of 5x108 p.f.u. of AAV9-CMV-Cre 8 
at the time of UUO surgery generating RelΔTEC mice. To deplete c-Rel in the epithelial cells 9 
of the lung Relfl/fl mice received 5x108 p.f.u. of AAV9-CMV-Cre via intratracheal 10 
administration to generate RelΔAEC mice. Control mice received an equal dose of either 11 
AAV8-TBG-null or AAV-CMV-Null.  12 
 13 
Organ injury and fibrosis models 14 
Animals used were aged within 8 to 12 weeks old at the start of the experiments. Liver injury 15 
and fibrosis was induced using the carbon tetrachloride model. To induce acute liver injury, 16 
male mice received a single intraperitoneal dose of CCl4 at 2μl/g body weight (CCl4:olive oil 17 
at 1:1 [vol/vol]). To induce liver fibrosis, male mice received biweekly intraperitoneal 18 
injections of CCl4 at 2μl/g body weight (CCl4:olive oil at 1:3 [vol/vol]) for 8 weeks. Kidney 19 
fibrosis was induced using the unilateral ureteral obstruction (UUO) model. Briefly, following 20 
a laparotomy, the left ureter of female mice was ligated and cut under general anaesthesia. 21 
Lung fibrosis was induced using the bleomycin model. Briefly, male mice received a single 22 
intratracheal dose of either saline or bleomycin (0.015U) under general anaesthesia. 23 
Prophylactic intervention utilising the c-Rel small molecule inhibitor IT-603 (Calbiochem) 24 
was performed using daily intraperitoneal injections of either vehicle (DMSO) or IT-603 25 
24mg/kg starting 24 hours prior to CCl4 and on the day of bleomycin administration or UUO 26 
 25 
surgery. Therapeutic intervention in the MCD model utilising IT-603 or a DMSO control was 1 
commenced after 2 weeks of being on the diet. Mice received the 3 doses a week of the 2 
therapy for the duration of the experiment. Therapeutic intervention in the chronic CCl4 3 
model utilising IT-603 or a DMSO control was commenced after 3 weeks of CCl4 injury. Mice 4 
received the therapy the day before CCl4 administration. Partial hepatectomy was performed 5 
on male mice aged 12 to 14 weeks old. Briefly, under isoflurane general anesthesia, 6 
following a laparotomy the left and median lobes were exposed, ligated and excised100. In 7 
all surgical models appropriate pain relief was provided. 8 
 9 
Histology and Immunohistochemistry 10 
Formalin fixed, paraffin embedded tissue sections were stained with 0.1% Picrosirius red 11 
and H&E using established protocols. Immunohistochemistry was performed on 12 
deparaffinised sections by first blocking endogenous peroxidase activity using 0.6% 13 
hydrogen peroxide/methanol solution. Antigen retrieval was performed using antigen 14 
unmasking solution (Vector) for αSMA 1:1000 (F3777 Sigma), CD68 1:200 (OABB00472 15 
Aviva Systems Biology), CTGF 1:100 (ab6992 Abcam), Snail 1:50 (ab53519 Abcam),  16 
PFKFB3 1:50 (ab181861 Abcam), PCNA 1:4000 (ab18197 Abcam) and combined antigen 17 
unmasking solution and 0.2% trypsin for c-Rel 1:200 (SC-71 Santa Cruz) and NIMP-R14 18 
1:100 (Ab 2557 Abcam). Endogenous avidin and biotin were blocked for 20 minutes using 19 
an Avidin/Biotin Blocking Kit (Vector Laboratories). Non-specific binding was blocked using 20 
20% swine serum for 30 minutes and then the primary antibody was added overnight at 4°C. 21 
The next day slides were washed and incubated with biotinylated swine anti-rabbit 1:200 22 
(eo353 Dako), biotinylated goat anti-fluorescein 1:300 (BA-0601 Vector) or goat anti-rat 23 
1:200 (STAR80B Serotec). Slides were then washed and incubated with Vectastain Elite 24 
ABC Reagent. Staining was visualised using DAB peroxidase substrate kit and 25 
counterstained with mayers haematoxylin and then mounted. (TdT)-mediated dUTP nick 26 
 26 
end (TUNEL) labelling was carried out using the In-Situ Cell Death Detection kit (Merck, 1 
11684817910) according to the manufacturers’ protocol. Liver and lung tissue sections were 2 
analysed at 100x whereas kidney cortex was imaged at 200x using a Nikon Eclipse Upright 3 
microscope and NIS-Elements BR analysis software. A minimum of twelve consecutive non-4 
overlapping fields of liver, kidney and lung tissue were analysed per stain per mouse. For 5 
human sections a minimum of 5 fields were analysed per biopsy.       6 
 7 
 8 
Immunofluorescence staining 9 
Immunofluorescence was performed on deparaffinised sections. Antigen retrieval was 10 
performed using combined heat-mediated antigen unmasking solution (Vector) and then 11 
0.2% trypsin at 37°C for 25 minutes. Non-specific binding was blocked using 10% normal 12 
goat serum in TBS-T (Vector) for 1 hour followed by 1x casein (Vector) for 1 hour. The c-13 
Rel 1:50 (SC-71 Santa Cruz) and CD68 1:50 (clone KP1, thermofisher) primary antibodies 14 
were diluted in 10% normal goat serum in TBS-T and then slides were incubated in a 15 
humidified chamber overnight at 4°C. The next day slides were washed in TBS-T and then 16 
incubated with secondary antibodies; Alexa 594 donkey anti-rabbit (thermofisher) and Alexa 17 
647 donkey anti-mouse (thermofisher) diluted 1:200 in 10% normal goat serum in TBS-T for 18 
2 hours. Slides were then washed in TBS-T and stained with Hoechst stain for 15 minutes 19 
prior to mounting in vector mounting solution. Slides were imaged using a Zeiss LSM800 20 
with Airyscan  using Zen software. 21 
 22 
Immunofluorescence was performed on 4% paraformalydehyde fixed murine hepatic 23 
stellate cells cultured in chamber slides. Cells were permeabilised with 0.2% saponin, 24 
blocked with 1% bovine serum albumin (BSA) to limit non-specific binding then washed in 25 
TBS-T. The FITC conjugated αSMA (F3777 Sigma) primary antibody was diluted 1:1000 in 26 
TBS-T 1% BSA and then incubated at room temperature for 1 hour.  Slides were then 27 
 27 
washed in TBS-T and stained with Hoechst stain for 15 minutes prior to mounting in vector 1 
mounting solution. Slides were imaged at 20x magnification using a Zeiss LSM800 with 2 
Airyscan. Images were analysed using Zeiss Zen software image analysis nod). 3 
  4 
RNAScope 5 
In situ mRNA hybridization was performed on normal and fibrotic murine liver (chronic CCl4) 6 
and kidney (day 10 UUO) sections using RNAscope LS probes for Snail1 and PPIB control 7 
(451218 and 313918); Advanced Cell Diagnostics) as per the manufacturer’s instructions.  8 
 9 
Precision Cut Slices 10 
Tissue cores were generated using a 8mm Stiefel biopsy punch and then transferred to a 11 
metal mould and submerged in 3% low geling temperature agarose and allowed to set. 12 
Agarose embedded tissue cores were then cut using a Leica VT1200S microtome (Leica 13 
Biosystems, UK) to produced tissue slices (8 micron diameter and 250 micron depth) which 14 
were then cultured in BioR plates in our patented bioreactor platform patent 15 
(PCT/GB2016/053310). Liver PCLS were cultured in Williams E media supplemented with 16 
1% penicillin and streptomycin, glutamine, 100mM dexamethasone, insulin trasnferrin-17 
selenium X and 2% fetal bovine serum. Kidney slices were generated as above and cultured 18 
in DMEM-F12 (Gibco) supplemented with REGM SingleQuot Kit (Lonza) and 1% 19 
penicillin/streptomycin and L-glutamine. Human liver and kidney slices were treated 10 ng 20 
TGF1 to induce fibrosis. Tissue slices were treated ± 20 μM IT-603 c-Rel inhibitor. Murine 21 
liver PCS were generated from WT and Rel-/- mice were cultured ± 10ng TGF1 ± 50ng 22 
CTGF for 72 hours. All PCS were cultured at 37°C supplemented with 5% CO2 and media 23 
was changed daily. 24 
 25 
Cell Isolation 26 
 28 
Murine hepatocytes were isolated using a two-step perfusion method. Under terminal 1 
anaesthesia using pentobarbitol, mice underwent a laparotomy, the inferior vena cava was 2 
then cannulated and the superior vena cava was clamped to achieve retro-perfusion of the 3 
liver using the portal vein as an outlet. The liver was perfused sequentially with buffer a 4 
(Krebs Ringer buffer and EDTA) and then buffer B (Krebs Ringer buffer, CaCl2 and 1mg/ml 5 
Collagenase B) at a flow rate of 7mls per minute. In situ liver digestion was performed using 6 
collagenase from Clostridium histolyticum (Sigma). Post perfusion, the liver capsule was 7 
torn and hepatocytes were isolated by gently agitating the perfused liver in Krebs-ringer 8 
buffer and then sepreated into a single cell suspension using a 70-μm cell strainer. 9 
Hepatocytes were collected by three rounds of centrifugation (50g for 3 minutes) followed 10 
by washes in Krebs-Ringer buffer. A hepatocyte enriched fraction was obtained using a 40% 11 
Percoll density gradient (250g for 6 minutes). Pelleted hepatocytes were resuspended in 12 
10% FCS Williams E and then cultured for subsequent experiments. 13 
 14 
Bone marrow derived macrophages were isolated from the femur and tibia of WT and Rel-/- 15 
mice. Briefly, bone marrow was extracted by flushing the bones with 5% FCS HBSS- after 16 
which the cell suspension was washed and placed onto a 62% Percoll gradient and 17 
centrifuged (1000g for 30 minutes). The pellet contained polymorphonuclear cells and the 18 
interface mononuclear cells, which were then cultured for 10 days in RPMI-1640 media 19 
containing 10ng/ml MCSF to promote differentiation into mature macrophages. Mature 20 
macrophages were stimulated 100ng/ml LPS and 50ng/ml IFNγ to induce an M1 phenotype 21 
or 10ng/ml IL-4 and 10ng/ml IL-13 to induce an M2 phenotype. Control M0 macrophages 22 
received a complete media change without the addition of any additional factors. 23 
 24 
Total leukocytes for flow cytometry were prepared from the livers of control or injured mice. 25 
First, the liver was diced and then digested in RPMI supplemented with DNase and 26 
 29 
Collagenase B for 1 hour at 37°C. The cell suspension was then filtered through a 70-μm 1 
cell strainer and then layered onto a 33% Percoll density gradient and centrifuged (1000g 2 
for 20 minutes) the cell pellet was resuspended in ACK lysis buffer to eliminate red blood 3 
cells prior to staining. The non-parenchymal fraction located at the Percoll interface was 4 
used for flow cytometric validation of conditional knockout mice. 5 
 6 
Murine hepatic stellate cells (HSC) were isolated as previously described101 and grown in 7 
Nunc™ Lab-Tek™ II Chamber Slide™ System (thermoscientific) with complete media; 8 
Dulbecco's modified Eagle's medium containing 100 U/ml penicillin, 100 μg/ml streptomycin, 9 
2 mmol/L L-glutamine, and 16% foetal calf serum. After 3 days in culture, HSC were 10 
simulated for 24 hours with media only (control) or conditioned media collected from either 11 
WT or Rel-/- hepatocytes stimulated with 10ng TGF, or WT or Rel-/- M1 or M2 polarised 12 
bone marrow derived macrophages. Conditioned media was passed through a 0.3 micron 13 
filter prior to a 1:1 dilution in complete DMEM and addition to the qHSC. Cells were then 14 
fixed in 4% paraformalydehyde ready for immunofluorescence staining.  15 
 16 
Proximal tubule epithelial cells (PTECs) were isolated from the kidneys of WT and Rel-/- 17 
mice. Briefly, the cortex was the minced and digested with 1mg/ml collagenase IV at 37°C 18 
and then passed through a 40μm cell. The digest was then layered onto a discontinuous 19 
Percoll gradient with densities of 1.07 and 1.04 g/ml and centrifuged at 3000rpm for 30 20 
minutes at 4°C. The middle layer containing PTECs was washed in RPMI. PTEC were then 21 
resuspended in DMEM/F-12 supplemented with REGM SingleQuot kit (Lonza), 0.5% foetal 22 
calf serum, 100U/ml penicillin and 100ug/ml streptomycin. PTECs were seeded onto 23 
collagen coated plates for experiments.  24 
 25 
All cells were maintained in an incubator at 37°C in an atmosphere of 5% CO2. 26 
 30 
 1 
Flow cytometry 2 
Single cell suspensions were first resuspended in LIVE/DEAD™ Fixable Violet Dead Cell 3 
Stain (ThermoFisher) and then Fc blocked (CD16/32). Cells were then resuspended in 4 
FACS buffer (PBS 1% FCS) containing the antibodies for surface staining as listed in 5 
(Supplementary Table 2). Staining of intracellular antigens was performed by fixing the 6 
surface stained cells in 4% paraformaldehyde followed by permeabilisation using Perm 7 
Wash (BD Biosciences). Cells were then resuspended in Perm Wash containing the 8 
antibodies for intracellular staining. Cells were read on a FACSCanto II using FACSDIva 9 
software version 8 and analysed using FlowJo software version 10. 10 
 11 
Seahorse 12 
Mature bone marrow derived macrophages were seeded onto the seahorse cell culture 13 
microplate and the polarised using a combination of either LPS and IFN or IL-4 and IL-13 14 
to generated M1 and M2 macrophages respectively. The injection ports were then loaded 15 
with the following compounds: A 2.5M (45%) glucose, B 5mM oligomycin A, C 5mM FCCP 16 
and 100mM sodium pyruvate, D 5mM antimycin A and 5mM rotenone. Seahorse metabolic 17 
flux assay was then performed according the manufacturer’s instructions with 3 rounds of 2 18 
minute mix and 3 minute measure times. Flux assay measurements were normalised to total 19 
protein content determined by Bradford assay.  20 
 21 
Enzyme-linked immunosorbent assay 22 
Media samples collected from precision cut human liver, kidney and lung slices treated with 23 
IT-603. Quantifications of soluble human collagen 1A1 (COL1A1; DY6220, R&D systems) 24 
were performed as per manufacturer’s instructions.   Levels of pro-C3 ELISA was performed 25 
on undiluted media samples (Nordic Bioscience). Quantification of mouse connective tissue 26 
 31 
growth factor (CTGF; LS-F21342, LSBio) in the culture media collected from WT and Rel-/- 1 
hepatocytes stimulated  TGF1,  Pfkfb3fl/fl and Pfkfb3Δhep hepatocytes stimulated  TGF1 2 
and WT hepatocytes stimulated  TGF1 and treated  PFKFB3i was performed as per 3 
manufacturer’s instructions.    4 
 5 
Colorimetric assays 6 
Lactate dehydrogenase (Thermo Fisher), L-Lactate (Abcam ab65331) and Glucose (Abcam 7 
ab65333) assay kits were performed as per manufacturer’s instructions. Serum 8 
transaminase quantification was performed at the chemical pathology department at the 9 
Royal Victoria infirmary according to standard protocols.  10 
 11 
Protein preparation for mass spectrometry 12 
For secretome analysis proteins were precipitated from 1.5 ml of conditioned media 13 
(hepatocyte secretome) or 1 ml of conditioned media (macrophage secretome) using a 14 
chloroform/methanol protein precipitation. Protein pellets were resuspended in a final 15 
volume of 25 µl SDS lysis buffer (5% SDS, 50 mM triethylammonium bicarbonate (TEAB) 16 
pH 7.5).  Protein concentration was determined by the bicinchoninic acid assay (BCA). A 17 
total of 2.4 µg protein (hepatocyte secretome) or 1 µg (macrophage secretome) was reduced 18 
by incubation with 5mM tris(2-carboxyethyl)phosphine (TCEP) for 15 minutes at 37°C, and 19 
subsequently alkylated with 40 mM iodoacetamide for 30 minutes at room temperature in 20 
the dark. Protein digestion was performed using the suspension trapping (S-Trap™) sample 21 
preparation method using the manufacturer’s guidelines (ProtiFi™, Huntington NY). Briefly, 22 
2.5 µl of 12% phosphoric acid was added to each sample, followed by the addition of 2 µg 23 
trypsin. This was added to 165 µl S-Trap binding buffer (90% methanol in 100mM TEAB, 24 
pH 7.1) in the S-Trap Micro spin column. The samples were centrifuged at 4,000 x g for 1 25 
minute until all the solution passed through the filter. Each S-Trap Mini-spin column was 26 
 32 
washed with 150 µl S-trap binding buffer by centrifugation at 4,000 x g for 1 minute. This 1 
process was repeated for a total of four washes. 25 µl of 50 mM TEAB, pH 8.0 containing 2 
0.5 µg trypsin was added to each sample, followed by proteolytic digestion for 3 hours at 3 
47°C using a thermomixer (Eppendorf) without shaking. Peptides were eluted with 50 mM 4 
TEAB pH 8.0 and centrifugation at 1,000 x g for 1 minute. Elution steps were repeated using 5 
0.2% formic acid and 0.2% formic acid in 50% acetonitrile, respectively. The three eluates 6 
from each sample were combined and dried using a speed-vac before storage at -80°C. 7 
 8 
Quantitative mass spectrometry 9 
Peptides were dissolved in 5% formic acid, and each sample was independently analysed 10 
on an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific), 11 
connected to a UltiMate 3000 RSLCnano System (Thermo Fisher Scientific). Peptides were 12 
injected on an Acclaim PepMap 100 C18 LC trap column (100 μm ID × 20 mm, 3 μm, 100 Å) 13 
followed by separation on an EASY-Spray nanoLC C18 column (75 ID μm × 500 mm, 2 μm, 14 
100 Å) at a flow rate of 300 nl min−1. Solvent A was water containing 0.1% formic acid, and 15 
solvent B was 80% acetonitrile containing 0.1% formic acid. The gradient used was as 16 
follows: solvent B was maintained at 3% for 5 minutes, followed by an increase from 3 to 17 
35% B in 120 min, 35-90% B in 0.5 min, maintained at 90% B for 4 minutes, followed by a 18 
decrease to 3% in 0.5 min and equilibration at 3% for 10 minutes. The Orbitrap Fusion Tribrid 19 
mass spectrometer was operated in data dependent, positive ion mode. Full scan spectra 20 
were acquired in a range from 400 m/z to 1600 m/z, at a resolution of 120,000, with an 21 
automated gain control (AGC) of 4e5 and a maximum injection time of 50 ms. Precursor 22 
ions were isolated with a quadrupole mass filter width of 1.6 m/z and HCD fragmentation 23 
was performed in one-step collision energy of 30%. Detection of MS/MS fragments was 24 
acquired in the linear ion trap in rapid mode using a Top 3s method, with an AGC target of 25 
 33 
1e4 and a maximum injection time of 45 ms. The dynamic exclusion of previously acquired 1 
precursors was enabled for 35 s with a tolerance of +/-10 ppm.  2 
 3 
Mass spectrometry data analysis 4 
All spectra were analysed using MaxQuant 1.6.6.0 and searched against a SwissProt Mus 5 
musculus fasta file (25,691 entries, downloaded 14/09/2018). Peak list generation was 6 
performed within MaxQuant and searches were performed using default parameters and 7 
the built-in Andromeda search engine. The following search parameters were used: first 8 
search peptide tolerance of 20 ppm and second search peptide tolerance 4.5 ppm. Cysteine 9 
carbamidomethylation was set as a fixed modification and oxidation of methionine was set 10 
as variable modification. A maximum of two missed cleavage sites were allowed. False 11 
Discovery Rates were set to 1% for both peptides and proteins. LFQ intensities were 12 
calculated using the MaxLFQ algorithm from razor and unique peptides with a minimum ratio 13 
count of two peptides across samples. Statistical analysis was performed using R Studio 14 
(version 1.1.456.0). The data was first filtered to remove proteins that matched to a 15 
contaminant or a reverse database, or which were only identified by site. Only proteins 16 
identified by a minimum of 2 unique peptides were retained. LFQ intensity values were log2 17 
transformed, and data filtered to contain at least 2 valid values in each group of the 18 
comparison being tested. The R package LIMMA was used for statistical analysis, where 19 
proteins with a p-value ≤ 0.05 were considered as statistically significant. Proteins were 20 
classified as unique if they were detected in all replicates of at least one group and none of 21 
the replicates of at least one other group. 22 
 23 
Meso Scale Discovery  24 
The cytokines Il-6, Cxcl1, Cxcl2, Cxcl10, Ccl2, Ccl3, Ccl4 and Ccl5 were quantified in 25 
conditioned media collected from WT and Rel-/- hepatocytes stimulated  IL-1 or TGF1,  26 
 34 
WT and Pfkfb3-/- hepatocytes stimulated  TGF1 or WT hepatocytes stimulated  TGF1 1 
and treat  PFKFB3i using a custom U-Plex MSD panel according to the manufacturer 2 
instructions.  3 
 4 
Hydroxyproline assay 5 
Tissue samples were hydrolysed in 1ml 6N HCl acid overnight at 110°C. Hydroxyproline 6 
standards were made up from 4mg/ml Calbiochem stocks. 20 l of the samples were then 7 
pipetted in triplicate. Solutions A and B were then prepared as follows: A. 0.282g Chloramine 8 
T-hydrate, 2ml water, 4ml isopropanol, 16ml Citrate Acetate buffer. Citrate acetate buffer 9 
consisted of 5% w/v Citric Acid, 1.2% w/v Glacial Acetic Acid, 7.24% w/v Sodium Acetate, 10 
3.4% w/v Sodium Hydroxide with sterile water added for a complete volume of 200ml. B. 11 
2.5g p-dimethylaminobenzaldehyde, 9.3ml Isopropanol, 7.3ml Perchloric acid. 100 l of 12 
solution A was added to each well of the 96 well plate and allowed to oxidise at room 13 
temperature for 30 minutes. 100 l of Solution B was the added to each well. The plate was 14 
then incubated at 60°C for 30 minutes and then measured using a spectrophotometric plate 15 
reader at 570nm.  16 
 17 
RNA isolation, cDNA synthesis and RT-PCR 18 
RNA was extracted from tissues using the QIAGEN RNeasy Mini kit (QIAGEN) according to 19 
the manufacturer’s instructions. RNA was then treated with DNase and then used to 20 
synthesise cDNA using the GoScript Reverse Transcription System (Promega). Real time 21 
PCR was performed using SYBR Green jumpstart ready mix and the primers listed in 22 
(Supplementary Table 3). 23 
 24 
Chromatin Immunoprecipitation (ChIP) assay 25 
 35 
Cross-link chromatin was prepared from WT hepatocytes after 4-hour treatment with TGFβ1 1 
or M0, M1 and M2 polarised WT macrophages. ChIP was performed using 50μg of cross-2 
linked chromatin (sheared by sonication to ~500bp fragments) per reaction and 10μg of 3 
antibody to c-Rel (SC-71 Santa Cruz) or Rabbit IgG control (Abcam) for 4 
immunoprecipitation. 3000bp sequence upstream of the transcription start site was analysed 5 
in silico using Promo (available via the ALGGEN server, Polytechnic University of Catalonia, 6 
Barcelona, Spain) for potential transcription factor binding sites. ChIP primers were then 7 
designed to amplify Snail, Pfkfb1 or Pfkfb3 promoter regions and the primers listed in 8 
(Supplementary Table 4). 9 
 10 
Transient transfection and luciferase assay 11 
U937-3xNF-kB-luc reporter cells (which express firefly luciferase driven by 3 NF-kB 12 
consensus sequences) were transiently transfected with either RelA or c-Rel pcDNA3 13 
expression vectors using the non-liposomal Effectene kit (Qiagen) for 48h, according to 14 
manufacturer’s instructions. Luciferase assays were performed using the luciferase kit 15 
(Promega) and luciferase activity was normalised to protein concentration.  16 
 17 
Statistical Analysis 18 
Results are presented as means ± s.e.m. Graphpad prism version 8, was used to perform 19 
unpaired t-test or analysis of variance with a Tukey’s post hoc test for unmatched samples. 20 
For matched cell cultures either a paired t-test or paired Two-way analysis of variance with 21 
a Tukey’s post hoc test. * P<0.05, ** P<0.01, *** P<0.001 or **** P<0.0001 was considered 22 
statistically significant.  23 
 24 
Data availability 25 
 36 
Mass spectrometric raw data are available through the PRIDE repository 1 
(https://www.ebi.ac.uk/pride/archive/) and have been assigned the identifiers PXD017320. 2 
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Figure 1. c-Rel is a feature of chronic liver, kidney and lung disease in humans and 4 
epithelial c-Rel signalling regulates hepatic fibrogenesis and regeneration in mice  5 
(a) Representative images show c-Rel staining in normal and diseased liver, lung and kidney 6 
sections. (b) Graphs show average percentage area of c-Rel stained tissue in normal liver, 7 
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lung and kidney sections compared to diseased human liver (alcoholic liver disease (ALD), 1 
primary sclerosing cholangitis (PSC) and non-alcoholic steatohepatitis (NASH)), diseased 2 
kidney (focal segmented glomerular sclerosis (FSGS) and diabetic nephropathy (DN)) or 3 
lung disease, idiopathic pulmonary fibrosis (IPF). Data are mean ± s.e.m. in 7 healthy and 4 
11 diseased patient tissue for liver (p value = 0.0003), 5 healthy and 13 diseased patient 5 
tissue for kidney (p value = 0.0002) and 5 healthy and 8 diseased patient tissue for lung (p 6 
value <0.0001). (c) FACS plot showing the Mean Fluorescence Intensity (MFI) of GFP in 7 
hepatocytes, cholangiocytes (EPCAM+) and non-parenchymal (EpCAM-) cells from the liver 8 
of Relflfl (grey) and RelΔAlb (blue) mice. (d) Representative images show c-Rel staining 5 9 
mice/group in olive oil Relflfl mice and CCl4 injured Relflfl and RelΔAlb mice. (e-f) Histological 10 
assessment and representative images of (e) αSMA (p value = 0.005) and (f) PCNA (p value 11 
= 0.005) stained liver sections in acute CCl4 injured Relflfl and RelΔAlb mice. Data are mean 12 
± s.e.m. in 5 mice/group. Scale bars equal 50 microns. All P values were calculated using a 13 



















Figure 2. c-Rel signalling regulates epithelial inflammatory responses via regulation 3 
of Pfkfb3 (a) Heatmap showing secreted IL6, Cxcl1, Cxcl2, Cxcl10, Ccl2, Ccl3, Ccl4 and 4 
Ccl5, measured by MSD in the media of hepatocytes isolated from WT and Rel-/- mice and 5 
stimulated ± IL-1β. (b) Graph shows quantification of neutrophil (p value = 0.0012) and 6 
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macrophage (p value = 0.0039) numbers in the liver of acute CCl4 injured Relflfl and RelΔHep 1 
mice. (c) Heatmap showing secreted IL6, Cxcl1, Cxcl2, Cxcl10, Ccl2, Ccl3, Ccl4 and Ccl5, 2 
measured by MSD in the media of hepatocytes isolated from WT and Rel-/- mice and 3 
stimulated ± TGFβ1. (d) Volcano plots show differentially expressed proteins detected by 4 
proteomic analysis of the secretome of WT control and WT TGFβ1 treated hepatocytes (left) 5 
and TGFβ1 treated WT and Rel-/- hepatocytes (right). (e) Venn diagram shows the number 6 
of differentially expressed proteins in TGFβ1 treated WT hepatocytes compared to control 7 
WT hepatocytes (Blue) and number of differentially expressed proteins in TGFβ1 treated 8 
WT hepatocytes compared to TGFβ1 treated Rel-/- hepatocytes (Orange). The overlap 9 
denotes c-Rel dependent secreted proteins in response to TGFβ1 stimulation. (f) 10 
Representative images show CTGF staining in the liver of 6 mice/group acute CCl4 injured 11 
Relflfl and RelΔHep mice. (g) Graphs show seahorse analysis of glycolysis (extracellular 12 
acidification rate, ECAR) and mitochondrial respiration (oxygen consumption rate, OCR) in 13 
WT and Rel-/- hepatocytes stimulated ± TGFβ1. Where A-D vertical lines refer to the 14 
administration of the following compounds: A – Glucose, B – Oligomycin, C- Pyruvate and 15 
FCCP, D – Rotenone and Antimycin A. (h) Representative images show Pfkfb3 staining in 16 
a minimum of 5 mice/group of olive oil control and CCl4 injured liver. (i) Graph shows mRNA 17 
expression of Pfkfb3 in WT and Rel-/- hepatocytes stimulated ± TGFβ1. (p value = 0.0008) 18 
(j) Quantification of neutrophil (p value= 0.0097) and macrophage (p value = 0.0002) 19 
numbers and histological assessment and representative images of αSMA (p value = 0.001) 20 
stained liver sections in acute CCl4 injured Pfkfb3flfl and Pfkfb3Δhep mice. P values were 21 
calculated using a unpaired two-sided T test. (k) Heatmap shows mRNA levels of fibrogenic 22 
genes; Tgfb1, Acta2, Col1a1, Col1a2, Timp1, Ctgf and inflammatory genes; Il1b, Il6, Tnfa, 23 
Cxcl1, Ccl2 and Ccl5 in acute CCl4 injured Pfkfb3flfl and Pfkfb3Δhep mice. Data in graphs are 24 
mean ± s.e.m. in 7 mice/genotype (c), n=5 Pfkfb3flfl and n=6 Pfkfb3Δhep mice (e), or a 25 
minimum of 3 independent cell isolations/condition. Scale bars equal 100 microns. (a, c, i) 26 
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P values were calculated using a two-way ANOVA with Tukey post-hoc t-test. (b, j, k) P 1 
values were calculated using unpaired two-tailed T-test (* P <0.05, ** P <0.01 and 2 







Figure 3. c-Rel signalling in macrophages is pro-fibrogenic and regulates 2 
macrophage plasticity 3 
(a) Histological assessment and representative images of Picrosirius red (collagen) stained 4 
liver sections in chronic CCl4 injured in Relflfl, RelΔAlb (p value = 0.0064) and RelΔLysM (p value 5 
= 0.0035) mice. Data are mean ± s.e.m. in 10 mice/group, scale bar equals 100 microns. (b) 6 
Representative immuno-fluorescence images show c-Rel (red), CD68 (green) and nuclear 7 
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(blue) staining in human diseased liver (n=11), kidney (n=13) and lung (n=8) sections. 1 
Yellow arrows denote co-localisaton of c-Rel and CD68. Scale bars equal 20 microns. (c) 2 
Representative bright-field images of WT and Rel-/- M1 and M2 polarised BMDMs in 3 3 
independent cell isolations. Scale bar = 50 microns (d) Heat map shows mRNA expression 4 
of Nos2, Il12, Tnfa, Il6, Il1b, Arg1, Ym1, Il13, Hgf and Egf in M0, M1 and M2 polarised WT 5 
and Rel-/- BMDM respectively. (e) Graphs show glycolysis (extracellular acidification rate, 6 
ECAR) and mitochondrial respiration (oxygen consumption rate, OCR) in M1 and M2 7 
polarised WT and Rel-/- BMDM respectively. Where A-D vertical lines refer to the 8 
administration of the following compounds: A – Glucose, B – Oligomycin, C- Pyruvate and 9 
FCCP, D – Rotenone and Antimycin A (f) Graphs show mRNA expression of Pfkfb3 (p value 10 
= 0.029) and Pfkfb1 (p value = 0.0031) in M1 and M2 polarised WT and Rel-/- BMDMs. Data 11 
are mean ± s.e.m of n=3 independent cell isolations. (a, d) P values were calculated using 12 
a two-way ANOVA with Tukey post-hoc t-test. (f) P values calculated using an unpaired two-13 
side T test. P values equal *P<0.05 and **P<0.01. Asterisks on heatmaps denote 14 
significance between WT and Rel-/- macrophages in M1 or M2 responsive genes in line with 15 
the M1 or M2 stimulation. There is no significant difference between M0 macrophages from 16 








Figure 4. c-Rel regulates pro-fibrogenic epithelial-macrophage crosstalk to 2 
accelerates fibroblast activation  3 
(a) Schematic shows Relfl/fl, RelΔLysM and RelΔAlb mice receiving CCl4 mediated acute liver 4 
injury. Mice were harvested at day 1 and day 5 post CCl4 injury during the inflammatory and 5 
resolution phases of wound healing (WH) respectively. (b) FACS quantification of the 6 
percentage (%) of CD11bHiF4/80Int inflammatory macrophages in uninjured liver and during 7 
the inflammatory (day 1) (p values = 0.0002 for RelΔAlb  and 0.00012 RelΔLysM mice) and 8 
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resolution (day 5) (p values = 0.0037 for RelΔAlb  and 0.0002 RelΔLysM mice) phases of WH 1 
in acute CCl4 injured Relflfl, RelΔAlb and RelΔLysM mice. (c) FACS quantification of the 2 
percentage (%) of iNOS+ (p values = 0.0033 for RelΔAlb  and 0.0002 RelΔLysM mice) and 3 
ARG1+ (p values = 0.0043 for RelΔAlb  and 0.0001 RelΔLysM mice) inflammatory macrophages 4 
during the inflammatory and resolution phases of WH respectively in acute CCl4 injured 5 
Relflfl, RelΔLysM and RelΔAlb mice. Data in graphs are mean ± s.e.m of n=4 independent cell 6 
isolations. (d) Heatmap shows mRNA expression of inflammatory genes; Cxcl1, Cxcl2, Ccl2, 7 
Il1b and Il6 in primary hepatocytes isolated from Relflfl, RelΔLysM and RelΔAlb mice during the 8 
inflammatory phase of WH. (e) Representative immuno-fluorescence images of αSMA 9 
(green) and nuclear (blue) staining, scale bar = 50 microns. (f) Graph showing quantification 10 
of αSMA stained area (f) in WT hepatic stellate cells cultured in media only (control) or 11 
conditioned media from WT or Rel-/- hepatocytes treated ± TGFβ1 (p value = 0.0153) or WT 12 
or Rel-/- M1 and M2 (p value = 0.024) polarised macrophages. Data are mean ± s.e.m of 13 
n=3 independent cell isolations. (b, c, f) P values were calculated using a two-way ANOVA 14 
with Tukey post-hoc t-test or an unpaired two-tailed t-test (* P <0.05, ** P <0.01 and *** P 15 
<0.001). (g) Model shows c-Rel-Pfkfb3 dependent paracrine epithelial-macrophage 16 









Figure 5. Epithelial or macrophage specific deletion of c-Rel limits renal and 2 
pulmonary fibrosis 3 
 (a) Histological quantification and representative images of Picrosirius red stained collagen 4 
in UUO injured kidneys of Relflfl, RelΔTEC (p value = 0.0013) and RelΔLysM (p value = 0.0002) 5 
mice and αSMA positive myofibroblasts in UUO injured kidneys of Relflfl, RelΔTEC (p value = 6 
0.002) and RelΔLysM mice (p value = 0.0005). (b) Histological quantification and 7 
representative images of Picrosirius red stained bleomycin injured lungs of Relflfl, RelΔAEC (p 8 
value = 0.0155) and RelΔLysM (p value = 0.0004) mice and αSMA stained bleomycin injured 9 
lungs of Relflfl, RelΔAEC (p value = 0.0161) and RelΔLysM (p value = 0.0013) mice. Data are 10 
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mean ± s.e.m. in a minimum of 7 mice/group for the kidney and 10 mice/group for the lung. 1 
Scale bars equal 100 microns. All P values were calculated using a one-way ANOVA with 2 























Figure 6. Epithelial and macrophage c-Rel signalling synergistically promote hepatic 2 
fibrosis but antagonistically regulate hepatic regeneration in mice  3 
(a) Schematic shows the timeline of intravenous injection administration of adeno-4 
associated virus expressing Cre recombinase (AAV-TBG-Cre) to Relflfl or RelΔLysM mice to 5 
create RelΔHep and RelΔHep/ΔLysM prior to chronic CCl4 injury. (b) Histological quantification 6 
and representative images of Picrosirius red stained sections from chronic CCl4 injured 7 
Relflfl, RelΔHep (p value = 0.0093), RelΔLysM (p value = 0.0074) and RelΔHep/ΔLysM (p value = 8 
0.0001) mice. (c) Histological quantification and representative images of αSMA stained 9 
sections from chronic CCl4 injured Relflfl, RelΔHep (p value = 0.028), RelΔLysM (p value = 0.023) 10 
and RelΔHep/ΔLysM (p value = 0.0001) mice. (d) Histological quantification and representative 11 
images of CD68 (macrophages) sections from chronic CCl4 injured Relflfl, RelΔHep (p value = 12 
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0.0316), RelΔLysM (p value = 0.0181) and RelΔHep/ΔLysM (p value = 0.00012) mice. (e) 1 
Histological quantification and representative images of PCNA stained sections from chronic 2 
CCl4 injured Relflfl, RelΔHep (p value = 0.0008), RelΔLysM (p value = 0.0106) and RelΔHep/ΔLysM 3 
mice. Data are mean ± s.e.m. in 5 mice/group. Scale bars equal 100 microns. All P values 4 
were calculated using a one-way ANOVA with Tukey post-hoc t-test (* P <0.05, ** P <0.01, 5 








Figure 7: Pharmacological inhibition of c-Rel limits fibrogenesis in murine models of 2 
liver, kidney and lung injury  3 
(a-c) Diagrams show experimental timelines of CCl4, UUO or bleomycin induced liver, kidney 4 
or lung fibrosis ± prophylactic IT-603 (c-Rel inhibitor) therapy. Histological quantification and 5 
representative images of αSMA stained liver (p value = 0.0031)  and Picrosirius red stained 6 
kidney (p value = 0.0099) or lungs (p value = 0.01)  following their respective injury. Data 7 
are mean ± s.e.m. in 7, 7 and 10 mice/group for liver, kidney and lung respectively. (d-e) 8 
Diagrams show experimental timelines of methionine choline deficient diet (MCD) fed or 9 
chronic CCl4 induced liver fibrosis ± therapeutic administration of IT-603. Histological 10 
quantification and representative images of Picrosirius red stained MCD (p value = 0.0044)  11 
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or chronic CCl4 (p value = 0.001) injured livers pre-treatment and ± therapeutic 1 
administration of IT-603. Data are mean ± s.e.m. in 5 pre-treatment mice, 8 vehicle treated 2 
MCD mice and 7 IT-603 treated MCD fed mice. Data are mean ± s.e.m. in 5 pre-treatment 3 
mice, 7 vehicle treated chronic CCl4 injured mice and 7 IT-603 treated chronic CCl4 injured 4 
mice. Scale bars equal 100 microns. (a-c) P values calculated using two-sided student T 5 
Test. (d-e) P values were calculated using a one-way ANOVA with Tukey post- hoc t-test. P 6 



















Figure 8: Pharmacological inhibition of c-Rel limits fibrogenesis in human precision 2 
cut liver slices 3 
(a-b) Representative images and histological quantification of (a) Picrosirius red (p value = 4 
0.0009) and (b) αSMA (p value = 0.0006) stained liver slices ± TGFβ1 ± IT-603 therapy. Red 5 
line denotes the value for the T=0 slice. (c-d) Quantification of (c) soluble collagen (p value 6 
= 0.0023) and (d) the neo-epitope pro C3 (p value 0.0286) released from fibrotic liver slices 7 
± IT-603 therapy. (e) Graph showing average LDH release in the media expressed as a 8 
percentage (%) of positive control (LDH levels in media from a PCS where maximal death 9 
was induced by multiple freeze/thaws – normalized to media volume) where p values = 10 
0.0044 and 0.0004 for IT-603 and IT-603+TGFβ1 respectively. Images are representative 11 
of n=3 independent slice experiments. Data are mean ± s.e.m. and representative of slices 12 
generated from 3 independent donors performed in duplicate. Scale bars equal 100 microns. 13 
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P values were calculated using two-way ANOVA with Tukey post- hoc t-test (*P<0.05, 1 















Extended data Fig 1. c-Rel correlates with disease progression in chronic kidney 3 
disease and is elevated in chronic lung disease. Investigation of the cell specific 4 
actions of c-Rel in preclinical models of liver injury.  5 
(a) Graph showing average percentage area of c-Rel stained tissue in (n=5)  normal lung and (n=7)  6 
chronic obstructive pulmonary disorder (COPD) (P value = 0.0003). (b) Graph showing average 7 
percentage area of c-Rel stained tissue in (n=5) normal human kidney and patients with stable (n=4, 8 
p value =0.0185)  or progressive kidney disease (n=8, p value = 0.003). Normal vs progressive p 9 
value <0.0001) (c) Graphs showing the Mean Fluorescence Intensity (MFI) of GFP in hepatocytes 10 
(p value = 0.0026), Cholangiocytes (EPCAM+, p value = 0.0026) and non-parenchymal (EPCAM-) 11 
cells from the livers of Relfl/fl and RelΔAlb mice. Data are mean ± s.e.m of 3 mice/group. (d) Heatmap 12 
showing gene expression of Cxcl1, Cxcl2, Ccl2, Cxcl9, Cxcl10, Il1b, Il6 and Tnfa in olive oil vehicle 13 
control and acute CCl4 injured Relflfl and RelΔAlb mice. Asterisk denotes significance between CCl4 14 
injured Relflfl and RelΔAlb mice; there is no significant difference between olive oil treated groups. (e) 15 
Histological assessment of αSMA, PCNA and CD68 stained liver sections in acute CCl4 injured Rel
flfl 16 
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and RelΔLrat mice. Data in graphs are mean ± s.e.m of n=5. (a, c, e) P values were calculated using 1 
unpaired two-sided T test. (b) P value was calculated using a one-way ANOVA with Tukey post-hoc 2 

















Extended data Fig 2. c-Rel regulates epithelial dedifferentiation and fibrogenic gene 2 
expression. (a) Representative images of c-Rel staining in CCl4 injured Relflfl and RelΔHep mice. 3 
Representative of n=7 mice/group. Scale bar represents 100m. (b) Graph shows mRNA levels of 4 
inflammatory cytokines Tnfa, Il1b (p=0.00038) and Il6  (p value = 0.022)and the inflammatory 5 
chemokines Cxcl1 (p value = 0.0034), Cxcl2 (p=0.054) and Ccl2 (p=0.0029), in CCl4 injured livers of 6 
Relfl/fl and RelHep mice. Data are mean ± s.e.m of 7 mice/group. (c) Heatmap showing relative mRNA 7 
expression of Il-6, Cxcl1, Cxcl2, Ccl2, Ccl4 and Ccl5 in WT and Rel-/- proximal tubular epithelial cells 8 
(PTEC) stimulated with or without TGFβ1. (d) Graphs show relative levels of Ctgf (p value = 0.034), 9 
Ctsd (p= 0.039), Serpine1 (p=0.04) and Bmp1 (p=0.0054) protein expressed as Intensity in control 10 
and TGFβ1 treated WT and Rel-/- hepatocytes. Data are from 4 independent cell isolations/group. 11 
(e) Quantification of soluble collagen (pg/ml) released from precision cut liver slices (PCLS) 12 
generated from WT and Rel-/- liver, stimulated ± TGFβ1 ± CTGF where (control p value = 0.012 and 13 
TGFβ1 p value = 0.045). Data are from PCLS generated 3 different donors/genotype. (b,d) P values 14 
were calculated using unpaired two-sided t-test. (d) P values were calculated using the R package 15 





Extended data Fig 3: c-Rel regulates metabolic enzymes to induce epithelial 3 
dedifferentiation and fibrogenic gene expression. (a) Seahorse analysis of basal (p<0.0001) 4 
and maximal (p<0.0001) glycolysis (extracellular acidification rate, ECAR) and basal (p<0.0007) and 5 
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maximal (p<0.0004) mitochondrial respiration (oxygen consumption rate, OCR) in WT and Rel-/- 1 
hepatocytes stimulated ± TGFβ1. (b) Graph shows mRNA expression of Pfkfb1 in WT and Rel-/- 2 
hepatocytes stimulated ± TGFβ1. (c) Graph shows mRNA expression of Pfkfb3 in WT and Rel-/- 3 
hepatocytes stimulated ± IL-1β. (p value=0.025) (d) Schematic representation of RelA, NF-κB1 and 4 
NF-κB binding sites in the murine Pfkfb1 and Pfkfb3 promoters. (e) ChIP analysis of c-Rel at the 5 
proximal and distal regions of the Pfkfb1 promoter and the proximal (p<0.0001) and distal (p=0.0185) 6 
regions of the Pfkfb3 promoter in WT hepatocytes treated ± TGFβ1. (f) Representative images show 7 
PFKFB3 immunohistochemical staining in liver sections from acute CCl4 injured Pfkfb3
flfl and 8 
Pfkfb3Δhep mice. Images are representative of n=5 mice/group. Scale bar is 100m. (g) Graphs show 9 
media lactate in control and TGFβ1 (p=0.0064) stimulated and glucose levels in control (p=0.0227) 10 
and TGFβ1 (p=0.00284) stimulated in hepatocytes isolated from Pfkfb3flfl and Pfkfb3Δhep mice and 11 
stimulated ± TGFβ1. (h) Heatmap showing secreated Il-6, Cxcl1, Cxcl2, Cxcl10, Ccl2, Ccl3, Ccl4 12 
and Ccl5, measured by MSD in the media of hepatocytes isolated from Pfkfb3flfl and Pfkfb3Δhep mice 13 
and stimulated ± TGFβ1. (i) Quantification of connective tissue growth factor (CTGF) in pg/ml in the 14 
culture media of hepatocytes isolated from Pfkfb3flfl and Pfkfb3Δhep mice and stimulated ± TGFβ1 15 
(p=0.0027) (j) Heatmap showing secreated Il-6, Cxcl1, Cxcl2, Cxcl10, Ccl2, Ccl3, Ccl4 and Ccl5, 16 
measured by MSD in the media of WT hepatocytes stimulated ± TGFβ1 ± the Pfkfb3 inhibitor 3PO. 17 
(k) Quantification of connective tissue growth factor (CTGF) in pg/ml in the culture media of WT 18 
hepatocytes stimulated ± TGFβ1 ± the Pfkfb3 inhibitor 3PO (p=0.0013). Data in graphs are mean ± 19 
s.e.m. in n=3 (g,i,k), n=4 (a,b,c) or n=5 (e) independent cell isolations/condition. All p values were 20 
calculated using a two-way ANOVA with Tukey post-hoc t-test (* P <0.05, ** P <0.01 and *** P 21 






Extended data Fig 4: c-Rel dependent Snail regulation in chronic liver and kidney 3 
disease 4 
(a) Representative images show expression of Snail in normal and chronic CCl4 injured liver. (b) 5 
Representative images show Snail in normal and UUO injured kidney. (c) Representative images of 6 
Snail transcript in epithelial cells detected by RNAScope in fibrotic chronic CCl4 injured fibrotic mouse 7 
liver. (d) Representative images of Snail transcript in epithelial cells detected by RNAScope in fibrotic 8 
UUO mouse kidney. All representative images are representative of n=5 mice/group. (a-b) Scale 9 
bars equal 100 microns (c-d) Scale bars equal 50 microns. (e) Graph showing mRNA levels of Snail 10 
in TGFβ1 treated hepatocytes (p=0.0001) and proximal tubular epithelial cells (PTEC) (p=0.02) 11 
isolated from WT and Rel-/- mice. Data in graphs are mean ± s.e.m. in n=3 independent cell 12 
isolations. (f) Graph showing ChIP analysis of c-Rel binding to distal (p=0.0074) and proximal 13 
(p=0.0063) regions of the Snail promoter in WT hepatocytes stimulated ± TGFβ1. Data in graphs 14 
are mean ± s.e.m. in n=5 independent cell isolations. P values were calculated using unpaired two-15 
sided t-test (e) and a ratio paired t-test (f) (* P <0.05, ** P <0.01 and *** P <0.001). 16 
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 1 
Extended data Fig 5: c-Rel regulates macrophage polarisation to drive tissue fibrosis. 2 
(a) Histological assessment and representative images of αSMA stained liver sections in acute CCl4 3 
injured in (n=13) Relflfl, (n=7) RelΔAlb (p=0.0116), and (n=10) RelΔLysM (p=0.0051) mice. Data are mean 4 
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± s.e.m. Scale bar equals 100 microns. P values were calculated using a one-way ANOVA with 1 
Tukey post- hoc t-test. (b) Representative low power immuno-fluorescence images show c-Rel (red), 2 
CD68 (green) and nuclear (blue) staining in diagnosed idiopathic pulmonary fibrosis lung sections. 3 
Yellow arrows denote co-localisaton of c-Rel and CD68. Scale bar equals 50 microns. Images are 4 
representative of n=8 IPF stained sections. (c) Heat map showing relative mRNA expression of 5 
fibrogenic markers; Tgfb1, Tgfb2, Tgfb3, TIMP1, Fn1, Pdgfa, Pdgfb, Mmp3, Mmp9 and Mmp13 in 6 
M1 and M2 polarised WT and Rel-/- BMDMs. (d) Graphs show, seahorse analysis of basal (p<0.0001) 7 
and maximal (p=0.0004) glycolysis (extracellular acidification rate, ECAR) and basal (p=0.0002) and 8 
maximal (p=0.0024) mitochondrial respiration (oxygen consumption rate, OCR) in M1 and M2 9 
polarised WT and Rel-/- BMDMs. Data are mean ± s.e.m. from 3 independent cell isolations/group. 10 
(e) ChIP analysis of c-Rel binding to distal and proximal (p=0.004) regions of the Pfkfb3 promoter 11 
and to distal and proximal (p=0.003) regions of the Pfkfb1 promoters in WT BMDM in response to 12 
M1 and M2 polarisation. Data are mean ± s.e.m. from 3 independent cell isolations/group. (d-e) P 13 
values were calculated using two-way ANOVA with Tukey post-hoc t-test . Denoted significance 14 
refers to comparisons between WT and Rel-/- macrophages polarised to either an M1 or M2 15 
phenotype. (f) Volcano plots show differentially expressed proteins detected by proteomic analysis 16 
of the secretome of M0, M1 and M2 polarised WT and Rel-/- BMDMs. (g) Graphs show relative levels 17 
of Galectin 1 (p=0.0031), Galectin 3 (p=0.0013), Vimentin (p=0.0128) and Matrix Metalloproteinase 18 
12 (MMP12) (p<0.0001) expressed as Intensity x108 in M0, M1 and M2 polarised WT and Rel-/- 19 
BMDMs. Data are mean ± s.e.m. from 4 independent cell isolations/group generated 4 different 20 
donors/genotype. P values were calculated using the R package LIMMA (* P <0.05, ** P <0.01 and 21 






Extended data Fig 6: Validation of epithelial specific deletion of c-Rel in kidney and 3 
lung fibrosis models.  4 
(a) Flow cytometry gating strategy to identify immune cells (CD45+), epithelial cells (EPCAM+) and 5 
endothelial cells (CD31+) isolated from the kidney or lungs of Relflfl, RelΔTEC or RelΔAEC mice 6 
respectively. (b-c) Ex vivo images of GFP fluorescence signal in the left and right kidneys, heart, 7 
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liver, lungs and spleen of RelΔTEC mice (b) or RelΔAEC mice (c) imaged using an In Vivo Imaging 1 
System (IVIS). Graph and flow cytometry histograms show the Mean Fluorescence Intensity (MFI) 2 
of GFP in EpCAM+, CD31+ , CD45+ and EpCAM-CD31-CD45- cells from the kidney of RelΔTEC and 3 
Relfl/fl  control mice (b) or from the lung of RelΔAEC and Relfl/fl  control mice (c), n=5 mice/group. (d) 4 
Heatmap showing mRNA levels of Tgfb1, Col1a1, Col1a2, Acta2 and Timp1 in control versus UUO 5 
kidney of Relflfl, RelΔTEC and RelΔLysM mice (left) or control versus bleomycin lung of Relflfl, RelΔAEC and 6 
RelΔLysM mice (right). Heatmap data are from 2 mice/group in control kidney or lung and 5 mice/group 7 
in the injured kidney or lung. (e) Quantification of hydroxyproline levels in nM per left lobe of lung 8 
tissue from bleomycin injured in Relflfl, RelΔAEC (p=0.0105), and RelΔLysM (p=0.0006) mice. (f) 9 
Histological assessment and representative images of TUNEL stained lung sections in day 3 10 
bleomycin injured in Relflfl, RelΔAEC, and RelΔLysM mice. Scale bar is 50 microns. Data are mean ± 11 
s.e.m. in n=5 mice/group. (g) Quantification of neutrophil numbers in UUO injured kidneys of Relflfl, 12 
RelΔTEC (p=0.0014) and RelΔLysM (p<0.0001) mice and macrophage numbers in UUO injured kidneys 13 
of Relflfl, RelΔTEC (p=0.0045) and RelΔLysM (p=0.0004) mice. (h) Quantification of neutrophil numbers 14 
in Bleomycin injured lungs of Relflfl, RelΔAEC and RelΔLysM mice and macrophage numbers in 15 
Bleomycin injured lungs of Relflfl, RelΔAEC (p=0.0018) and RelΔLysM (p=0.0327) mice. (e,g,h) Data are 16 
mean ± s.e.m. in a minimum of 7 mice/group for the kidney and 10 mice/group for the lung. P values 17 













Extended data Fig 7: Validation of single myeloid or dual hepatocyte- and myeloid- 3 
specific deletion of c-Rel in mice and analysis of fibrogenic gene expression in these 4 
mice during chronic liver injury.  5 
(a) FACS plot and graphs show the Mean Fluorescence Intensity (MFI) of GFP expression in 6 
hepatocytes, macrophages (CD45+F4/80+CD11b+) (p=0.011), T-cells (CD45+CD3+) and non-7 
parenchymal cells (CD45-) from the liver of Relflfl versus RelΔLysM mice, , n=3 mice/group. (b) FACS 8 
plot and graphs show the Mean Fluorescence Intensity (MFI) of GFP expression in hepatocytes 9 
(p=0.007), macrophages (CD45+F4/80+CD11b+) (p=0.007), T-cells (CD45+CD3+) and non-10 
parenchymal cells (CD45-) from the liver of Relflfl versus RelΔHep/ΔLysM mice, n=3 mice/group. (c) 11 
Heatmap showing mRNA levels of Tgfb1, Col1a1, Col1a2, Acta2 and Timp1 in the CCl4 injured liver 12 













Extended data Fig 8: c-Rel signaling in hepatocyte and macrophages differentially 3 
regulate liver regeneration via regulation of cell cycle genes and mitogenic factors. 4 
 (a) Histological assessment and representative images of PCNA positive hepatocytes in 5 
48h partial hepatectomy injured Relflfl, RelΔAlb (p=0.0003) and RelΔLysM (p=0.0096) 6 
mice. Scale bar is 100 microns. (b) Graph shows average liver/body weight ratio 48h post 7 
partial hepatectomy in Relflfl, RelΔAlb (p=0.0318) and RelΔLysM (p=0.0178) mice. (c) 8 
Heat map showing relative hepatic mRNA expression of cell cycle genes; Ccna1, Ccnd1, 9 
Ccne1, Cdk2, Cdk4 and mitogenic proteins; Hgf and Egf at 48h post partial hepatectomy 10 
in Relflfl, RelΔAlb and RelΔLysM mice. Data are mean ± s.e.m. in n=5 mice/group. P 11 
values were calculated using one-way ANOVA with Tukey post-hoc t- test (* P <0.05 and 12 






Extended data Fig 9: IT-603 attenuates fibrogenesis in murine models of fibrosis. 4 
(a) U937 cells stably expressing 3xNF-B-Luc reporter were transiently transfected with RelA or c-5 
Rel expression plasmids. Graph shows RelA and c-Rel induced NF-B luciferase reporter activity ± 6 
IT-603 therapy. Data are mean  s.e.m. P value = 0.0039. P value was calculated using an unpaired 7 
two-sided t-test (***P<0.001) of 3 independent experiments. (b-c) Histological quantification of αSMA 8 
stained kidney (p=0.0004) or lungs (p=0.009) following their respective injury. Data are mean ± 9 
s.e.m. in 7 and 10 mice/group for kidney and lung respectively. P values were calculated using an 10 
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unpaired two-sided t-test. (d) Histological quantification of αSMA stained chronic MCD diet injured 1 
livers at 2 weeks (pre-treatment) and 5 weeks ± therapeutic administration of IT-603 (p=0.0044). (e) 2 
Graphs showing relative hepatic expression of the fibrogenic genes; Tgfb1 (p=0.039), Acta2 3 
(p=0.028), Col1a1 (p=0.036), Col1a2, and Timp1(p=0.015) in 2-week (pre-treatment) and 5-week 4 
methionine choline deficient diet (MCD) fed mice ± therapeutic administration of IT-603. Data are 5 
mean ± s.e.m. in n=4 control mice 8 vehilce and n=7 IT-603 treated mice/group. (f) Histological 6 
quantification of αSMA stained chronic CCl4 injured livers at 3 weeks (pre-treatment) or 8 weeks ± 7 
therapeutic administration of IT-603 (p=0.0105). (g) Graphs showing relative hepatic expression of 8 
the fibrogenic genes; Tgfb1 (p=0.029), Acta2 (p=0.032), Col1a1 (p=0.04), Col1a2 (p=0.016), and 9 
Timp1 (p=0.009) in chronic CCl4 injured livers at 3 week (pre-treatment), 8 week and ± therapeutic 10 
administration of IT-603 (from weeks 3-8). Data are mean ± s.e.m. in n=4 control mice 7 experimental 11 
mice/group. (c,e) P values were calculated using one-way ANOVA with Tukey post-hoc t-test. (d,f) 12 









Extended data Fig 10: IT-603 attenuates fibrosis in ex vivo human tissues slice 3 
models of liver and kidney fibrosis. 4 
(a) Diagrams show the experimental timelines of TGFβ1 induced fibrosis in ex vivo normal human 5 
liver and kidney precision cut slices (PCS). (b) Representative images of CD68 stained liver and 6 
kidney tissue slices. (c) Representative images and histological quantification of Picrosirius red 7 
stained fibrotic kidney slices ± IT-603 therapy (p<0.0001). Representative images and histological 8 
quantification of αSMA stained fibrotic kidney slices ± IT-603 therapy (p<0.0001). Red line denotes 9 
the value for the T=0 slice. (e) Quantification of soluble collagen released from fibrotic kidney 10 
slices ± IT-603 therapy (p=0.0015). (f) Quantification of the neo-epitope pro C3 released from 11 
fibrotic kidney slices ± IT-603 therapy (p=0.0493). (g) Graph showing average LDH release in the 12 
media expressed as a percentage (%) of positive control (LDH levels in media from a PCS where 13 
 81 
maximal death was induced by multiple freeze/thaws – normalized to media volume). (IT-603 1 
p=0.023 and IT- 603+TGFβ1 p=0.02). Images representative of n=3 independent slice experiments. 2 
Data are mean ± s.e.m. and representative of slices generated from 3 independent donors 3 
performed in duplicate. Scale bars equal 100 microns. P values were calculated using two- way 4 
ANOVA with Tukey post- hoc t-test (*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001). 5 
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